Nektar Therapeutics (NKTR) EBT Margin (2010 - 2026)
Nektar Therapeutics (NKTR) recorded quarterly EBT Margin of 396.74% in Q1 2026, down 149.31% quarter-over-quarter from 159.13% in Q4 2025, and up 4656.0% on a YoY basis from 8.34% in Q1 2025.
Nektar Therapeutics (NKTR) EBT Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 396.74% for Q1 2026.
- In Q1 2026, EBT Margin rose 4656.0% year-over-year to 396.74%; the TTM figure through Mar 2026 stood at 273.59% (down 12605.0% YoY), while the FY2025 annual figure was 281.52%, down 16041.0% from the prior year.
- EBT Margin was 396.74% for Q1 2026 at Nektar Therapeutics, down from 159.13% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 24.0% in Q4 2024 to a low of 736.47% in Q2 2022.
- Historically, EBT Margin has averaged 295.55% across 5 years, with a median of 250.6% in 2022.
- The sharpest annual moves came in 2022 and 2023: EBT Margin slumped 29467 bps in 2022, then jumped 48686 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 256.75% in 2022, then soared by 33 bps to 171.03% in 2023, then surged by 114 bps to 24.0% in 2024, then plunged by 763 bps to 159.13% in 2025, then slumped by 149 bps to 396.74% in 2026.
- The last three EBT Margin figures came in at 396.74% (Q1 2026), 159.13% (Q4 2025), and 297.04% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | -396.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -396.74% |
| Dec 31, 2025 | -159.13% |
| Sep 30, 2025 | -297.04% |
| Jun 30, 2025 | -352.53% |
| Mar 31, 2025 | -443.30% |
| Dec 31, 2024 | 24.00% |
| Sep 30, 2024 | -153.57% |
| Jun 30, 2024 | -222.73% |
| Mar 31, 2024 | -170.23% |
| Dec 31, 2023 | -171.03% |
| Sep 30, 2023 | -190.10% |
| Jun 30, 2023 | -249.62% |
| Mar 31, 2023 | -634.81% |
| Dec 31, 2022 | -256.75% |
| Sep 30, 2022 | -250.60% |
| Jun 30, 2022 | -736.47% |
| Mar 31, 2022 | -363.66% |
| Dec 31, 2021 | -582.39% |
| Sep 30, 2021 | -520.02% |
| Jun 30, 2021 | -441.80% |